Last reviewed · How we verify

NCT03878888

Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control

Completed Phase 4 Last updated 17 December 2020
What this trial tests

Phase 4 trial testing Exparel 266 MG Per 20 ML Injection in Postoperative Pain in 52 participants. Completed in 1 July 2019.

Timeline
15 January 2019
Primary endpoint
1 July 2019
1 July 2019

Quick facts

Lead sponsorSt. Luke's Hospital, Pennsylvania
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment52
Start date15 January 2019
Primary completion1 July 2019
Estimated completion1 July 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

St. Luke's Hospital, Pennsylvania

Who can join

18 and older, any sex, with Postoperative Pain or Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine if Exparel (Liposomal Bupivacaine, an FDA approved drug) use in ultrasound guided Transversus Abdominis Plane (TAP) blocks may reduce opioid requirement use postoperatively, reduce pain scores postoperatively, reduce incidence of nausea in the postop period, and decrease length of hospital stay

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Exparel 266 MG Per 20 ML Injection

Trials testing the same drug.

Other recruiting trials for Postoperative Pain

Currently open trials in the same condition.

Other St. Luke's Hospital, Pennsylvania trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03878888.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing